Tema Etfs LLC Grows Position in Exelixis, Inc. $EXEL

Tema Etfs LLC raised its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 47.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 87,398 shares of the biotechnology company’s stock after acquiring an additional 28,139 shares during the quarter. Tema Etfs LLC’s holdings in Exelixis were worth $3,831,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in the stock. TriaGen Wealth Management LLC purchased a new stake in shares of Exelixis during the 3rd quarter worth approximately $2,024,000. BridgePort Financial Solutions LLC purchased a new position in Exelixis in the 3rd quarter valued at approximately $517,000. Candriam S.C.A. increased its stake in Exelixis by 18.4% in the 3rd quarter. Candriam S.C.A. now owns 696,104 shares of the biotechnology company’s stock valued at $28,749,000 after purchasing an additional 108,367 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Exelixis by 11.2% during the third quarter. Dimensional Fund Advisors LP now owns 4,180,912 shares of the biotechnology company’s stock worth $172,658,000 after purchasing an additional 419,596 shares during the last quarter. Finally, Allianz Asset Management GmbH boosted its position in Exelixis by 153.3% during the third quarter. Allianz Asset Management GmbH now owns 2,462,948 shares of the biotechnology company’s stock worth $101,720,000 after purchasing an additional 1,490,520 shares in the last quarter. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Exelixis

In other news, Director Jack L. Wyszomierski sold 99,574 shares of the firm’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $44.01, for a total transaction of $4,382,251.74. Following the sale, the director owned 279,942 shares in the company, valued at $12,320,247.42. This trade represents a 26.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Dana Aftab sold 47,918 shares of Exelixis stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $44.50, for a total value of $2,132,351.00. Following the completion of the sale, the executive vice president directly owned 616,106 shares of the company’s stock, valued at approximately $27,416,717. This represents a 7.22% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 362,849 shares of company stock worth $15,917,463. Company insiders own 2.82% of the company’s stock.

Exelixis Price Performance

Exelixis stock opened at $44.04 on Thursday. Exelixis, Inc. has a 12-month low of $32.38 and a 12-month high of $49.62. The stock has a market capitalization of $11.44 billion, a P/E ratio of 15.90, a P/E/G ratio of 0.96 and a beta of 0.42. The firm’s 50-day moving average is $42.70 and its two-hundred day moving average is $42.05.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.74 by $0.20. The firm had revenue of $598.66 million for the quarter, compared to analyst estimates of $609.17 million. Exelixis had a net margin of 33.73% and a return on equity of 36.29%. Exelixis’s revenue was up 5.6% compared to the same quarter last year. During the same quarter last year, the business earned $0.55 earnings per share. As a group, analysts forecast that Exelixis, Inc. will post 2.04 EPS for the current year.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Royal Bank Of Canada lowered their target price on Exelixis from $46.00 to $43.00 and set a “sector perform” rating on the stock in a report on Monday, March 2nd. Zacks Research downgraded Exelixis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, March 5th. UBS Group set a $41.00 price objective on shares of Exelixis in a research report on Monday, January 5th. Stifel Nicolaus increased their price objective on shares of Exelixis from $43.00 to $44.00 and gave the company a “hold” rating in a research note on Wednesday, February 11th. Finally, Citigroup downgraded shares of Exelixis from a “market outperform” rating to an “underperform” rating in a report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $46.94.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.